Compare McKesson Corporation (MCK) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Plby Group Inc — how do they compare? McKesson Corporation trades at $823 (market cap $97.35B), while Plby Group Inc trades at $1.22 (market cap $139.87M). The key difference: McKesson Corporation is far larger — about 696× Plby Group Inc's market cap, and McKesson Corporation pays a 0.39% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals.
| MCK | PLBY | |
|---|---|---|
Market Cap | $97.35B | $139.87M |
Sector | Health | Consumer Cyclical |
52-Week High | $995.69 | $2.71 |
52-Week Low | $659.01 | $1.11 |
Enterprise Value | $101.98B | $287.68M |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
PLBY Group trades at $1.21, up 3.42% with a market cap reflecting a P/S ratio of 1.02. The company shows improving fundamentals with five consecutive quarters of positive adjusted EBITDA and narrowing losses, though it remains unprofitable with negative ROE. Technical indicators signal bearish momentum despite neutral oscillators. Recent developments include Russell index inclusion and a strategic share repurchase program.
The outlook remains cautious due to persistent net losses and high debt levels, but operational improvements and brand repositioning offer potential upside. Key risks include execution challenges in licensing growth and competitive pressures in the leisure sector. Analyst consensus is strongly bullish with 75% buy ratings, suggesting confidence in the turnaround strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
